title: Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.
abstract: OBJECTIVE
  To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB).
  
  
  METHODS
  Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25 mg IVB and had a minimum follow-up of 60 months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05.
  
  
  RESULTS
  Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5 years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60 months. Mean CMT decreased from 403.5±142.2 μm at baseline to 313.7±117.7 μm over 5 years follow-up (p≤0.0001).
  
  
  CONCLUSIONS
  The early visual gains due to IVB were not maintained 5 years after treatment.
authors.affiliation: Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors.forename: J Fernando
authors.initials: JF
authors.lastname: Arevalo
authors.affiliation: Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina.
authors.forename: Andres F
authors.initials: AF
authors.lastname: Lasave
authors.affiliation: Retina Service, Instituto de Cirugia Ocular, San Jose, Costa Rica.
authors.forename: Lihteh
authors.initials: L
authors.lastname: Wu
authors.affiliation: Retina Service, Instituto de Cirugia Ocular, San Jose, Costa Rica.
authors.forename: Dhariana
authors.initials: D
authors.lastname: Acon
authors.affiliation: Retina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil.
authors.forename: Michel E
authors.initials: ME
authors.lastname: Farah
authors.affiliation: Department of Ophthalmology, Consorcio Hospital, General Universitario de Valencia, Valencia, Spain.
authors.forename: Roberto
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.affiliation: Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina.
authors.forename: Arturo A
authors.initials: AA
authors.lastname: Alezzandrini
authors.affiliation: Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina.
authors.forename: Veronica
authors.initials: V
authors.lastname: Fortuna
authors.affiliation: Department of Ophthalmology, University of Colorado School of Medicine, Denver, Colorado, USA.
authors.forename: Hugo
authors.initials: H
authors.lastname: Quiroz-Mercado
authors.affiliation: Department of Ophthalmology, University of Colorado School of Medicine, Denver, Colorado, USA.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Salcedo-Villanueva
authors.affiliation: Retina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil.
authors.forename: Mauricio
authors.initials: M
authors.lastname: Maia
authors.affiliation: Retina Service, Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela.
authors.forename: Martin
authors.initials: M
authors.lastname: Serrano
authors.affiliation: Retina Service, Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico.
authors.forename: Sergio
authors.initials: S
authors.lastname: Rojas
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D007843:Latin America; D008266:Macula Lutea / Q000000981:diagnostic imaging* / Q000187:drug effects; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D033401:Microscopy, Acoustic; D008875:Middle Aged; D009887:Ophthalmoscopy; D012189:Retrospective Studies; D013030:Spain; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Macula; Neovascularisation; Posterior Chamber; Retina; Treatment Medical